A switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) was associated with a better renal and bone profile. Some studies reported liver toxicity due to TDF. [1, 2] We aimed at investigating the effect of switching TDF to TAF on lipid, renal and hepatic safety profile.
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide and hepatic safety: a new paradigm?
Pellicano, G. F.;
2018-01-01
Abstract
A switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) was associated with a better renal and bone profile. Some studies reported liver toxicity due to TDF. [1, 2] We aimed at investigating the effect of switching TDF to TAF on lipid, renal and hepatic safety profile.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2018-Journal_of_the_International_AIDS_Society_pag-145.pdf
accesso aperto
Descrizione: Meeting Abstract
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
446.71 kB
Formato
Adobe PDF
|
446.71 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
